DGAP-News

MOLOGEN AG: Successful capital increase enables phase III study with immunotherapy MGN 1703 (colon cancer)

DGAP-News: MOLOGEN AG / Key word(s): Capital Increase
MOLOGEN AG: Successful capital increase enables phase III study with
immunotherapy MGN 1703 (colon cancer)

06.02.2014 / 17:27

---------------------------------------------------------------------

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN OR
INTO THE UNITED STATES, AUSTRALIA, CANADA, JAPAN OR SOUTH AFRICA.

PRESS RELEASE N° 02 / 2014 of 02/06/2014

MOLOGEN AG: Successful capital increase enables phase III study with
immunotherapy MGN 1703 (colon cancer)

Berlin, February 6, 2014 - MOLOGEN AG has successfully concluded the
capital increase, which was resolved yesterday. The issue price was set at
EUR 10.20 per new share. In the context of a private placement the capital
increase was fully placed with qualified investors in the amount of
1,541,244 shares (equivalent to 10 per cent of the current share capital).
The share capital will therefore be increased by issuing 1,541,244 new
no-par value bearer shares from currently 15,419,512 Euros to then
16,960,756 Euros. The gross proceeds amount to approximately 15.7 million
Euros.

The proceeds from the capital increase will be used to further strengthen
the equity base as well as to finance the development of the product
pipeline and the proceeds enable in particular to start the planned pivotal
clinical phase III study with MGN1703 in metastatic colorectal cancer.

Dr. Matthias Schroff, CEO of MOLOGEN AG: 'The planning for the pivotal
study has been largely completed. Thus, our cancer immunotherapy MGN1703
can enter into the final clinical phase this year in order to confirm the
previous excellent results in a significantly larger number of patients. We
are delighted about the trust of the investors.'

Further clinical study with MGN1703 in lung cancer in preparation
MNG1703, the cancer immunotherapy of MOLOGEN AG, can be used in various
indications. Hence, already in 2013 MOLOGEN has applied for a randomized,
controlled clinical study to evaluate the efficacy of MGN1703 in lung
cancer, which is scheduled to begin in the first half of 2014.



Disclaimer:
This announcement does not contain or constitute an offer of, or the
solicitation of an offer to buy or subscribe for, securities.

This release is not an offer of securities for sale in the United States of
America. Securities may not be offered or sold in the United States of
America absent registration or an exemption from registration under the
U.S. Securities Act of 1933, as amended (the 'Securities Act'). Any public